HUMA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Humacyte Inc (HUMA) is not a strong buy at the moment for a beginner investor with a long-term strategy. The stock exhibits bearish technical indicators, weak financial performance, and lacks significant positive catalysts. While options data shows a bullish sentiment, the overall picture suggests holding off on investing until further clarity is provided by upcoming earnings or other positive developments.
The technical indicators for HUMA are bearish. The MACD is below 0 and negatively contracting, the RSI is neutral at 27.496, and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading near its key support level of 0.755, with resistance levels at 0.953 and 1.151.
Humacyte has submitted a Marketing Authorization Application for its acellular tissue-engineered vessel, Symvess, to the Israel Ministry of Health. This could lead to future revenue opportunities if approved.
The stock has experienced a regular market decline of -5.42% and is trading in a bearish trend. Financial performance has been weak, with declining net income (-55.33% YoY) and EPS (-66.67% YoY). Additionally, the upcoming earnings report on March 27, 2026, has a consensus EPS estimate of -$0.14, which may further impact investor sentiment.
In Q3 2025, Humacyte's revenue remained flat at $753,000 YoY. Net income dropped significantly to -$17.51M (-55.33% YoY), and EPS fell to -$0.11 (-66.67% YoY). Gross margin improved slightly to 65.47%. Overall, the financials indicate weak growth and profitability.
Benchmark recently lowered its price target for HUMA from $11 to $10, maintaining a Buy rating. The adjustment reflects updated financial modeling, but the reduced price target suggests tempered expectations for the stock's performance.
